Alzheimer’s drug slows decline by 27%

WORLD

RISKS INCLUDE BRAIN BLEED

Experts hailed data on Wednesday showing a new drug can slow cognitive decline in Alzheimer’s patients, but warned that improvements were comparatively small and the treatment can have serious side effects. Preliminary data from a trial of lecanemab was released in September and found it slowed cognitive decline by 27% across an 18-month period. The trial data fleshes out those findings but also raises concern about the incidence of “adverse effects” including brain bleeds and swelling.